• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group.抗纤维化药物在新冠后间质性肺病管理中的作用：文献综述及专家工作组报告
Lung India. 2022 Mar-Apr;39(2):177-186. doi: 10.4103/lungindia.lungindia_659_21.
2
Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group.勘误：抗纤维化药物在新冠后间质性肺疾病管理中的作用：文献综述及专家工作组报告
Lung India. 2022 May-Jun;39(3):310. doi: 10.4103/0970-2113.343593.
3
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.可能对进展性肺纤维化非特发性肺纤维化间质性肺疾病患者有抗纤维化药物的价值。
BMC Pulm Med. 2019 Nov 12;19(1):213. doi: 10.1186/s12890-019-0937-0.
4
A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities.一项针对新冠后间质性肺异常症状患者抗纤维化药物使用情况的多中心调查研究。
Lung India. 2022 May-Jun;39(3):254-260. doi: 10.4103/lungindia.lungindia_568_21.
5
The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.抗纤维化治疗在进行性肺纤维化疾病中的广泛应用。
Expert Rev Respir Med. 2020 Oct;14(10):1001-1008. doi: 10.1080/17476348.2020.1784730. Epub 2020 Jul 6.
6
COVID-related fibrosis: insights into potential drug targets.COVID 相关纤维化：潜在药物靶点的新见解。
Expert Opin Investig Drugs. 2021 Dec;30(12):1183-1195. doi: 10.1080/13543784.2021.2010188. Epub 2021 Dec 1.
7
Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.抗纤维化疗法与进行性纤维化间质性肺疾病（PF-ILD）：基于INBUILD研究
J Clin Med. 2021 May 25;10(11):2285. doi: 10.3390/jcm10112285.
8
Diagnosis and Management of Fibrotic Interstitial Lung Diseases.纤维化间质性肺疾病的诊断与管理。
Clin Chest Med. 2021 Jun;42(2):321-335. doi: 10.1016/j.ccm.2021.03.008.
9
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.类风湿关节炎相关间质性肺疾病的治疗：光明与阴影
J Clin Med. 2020 Apr 10;9(4):1082. doi: 10.3390/jcm9041082.
10
Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience.抗纤维化药物治疗患者的慢性纤维性间质性肺炎急性加重：真实世界经验中的发生率和风险因素。
BMC Pulm Med. 2019 Jun 25;19(1):113. doi: 10.1186/s12890-019-0880-0.

引用本文的文献

1
Short- and long-term outcomes of pulmonary exposure to a sublethal dose of ricin in mice.肺暴露于蓖麻毒素亚致死剂量的短期和长期后果。
Sci Rep. 2024 May 21;14(1):11637. doi: 10.1038/s41598-024-62222-9.
2
Pulmonary Sequelae of Coronavirus Disease 2019.新型冠状病毒肺炎的肺部后遗症。
Phys Med Rehabil Clin N Am. 2023 Aug;34(3):573-584. doi: 10.1016/j.pmr.2023.04.005. Epub 2023 Apr 12.
3
Severe interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy.尽管接受了抗纤维化治疗，但新冠病毒感染后两年仍存在严重间质性肺疾病。
Lung India. 2022 Nov-Dec;39(6):587-588. doi: 10.4103/lungindia.lungindia_355_22.
4
Antifibrotic in interstitial lung diseases: When, where, and how long?间质性肺疾病中的抗纤维化治疗：何时、何处以及持续多久？
Lung India. 2022 Nov-Dec;39(6):491-494. doi: 10.4103/lungindia.lungindia_283_22.
5
Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group.勘误：抗纤维化药物在新冠后间质性肺疾病管理中的作用：文献综述及专家工作组报告
Lung India. 2022 May-Jun;39(3):310. doi: 10.4103/0970-2113.343593.

本文引用的文献

1
CT Lung Abnormalities after COVID-19 at 3 Months and 1 Year after Hospital Discharge.COVID-19 后 3 个月和 1 年出院后肺部 CT 异常。
Radiology. 2022 May;303(2):444-454. doi: 10.1148/radiol.2021211746. Epub 2021 Oct 5.
2
Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).了解 COVID-19 后间质性肺病的负担：英国间质性肺病-长新冠研究（UKILD-Long COVID）。
BMJ Open Respir Res. 2021 Sep;8(1). doi: 10.1136/bmjresp-2021-001049.
3
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?从急性呼吸窘迫综合征到肺纤维化：COVID-19 大流行的下一阶段？
Transl Res. 2022 Mar;241:13-24. doi: 10.1016/j.trsl.2021.09.001. Epub 2021 Sep 20.
4
Lung Fibrosis after COVID-19: Treatment Prospects.新冠病毒感染后肺纤维化：治疗前景
Pharmaceuticals (Basel). 2021 Aug 17;14(8):807. doi: 10.3390/ph14080807.
5
Post-COVID Interstitial Lung Disease - The Looming Epidemic.新冠后间质性肺病——即将到来的流行病。
J Assoc Physicians India. 2021 Jul;69(7):11-12.
6
Extension of Collagen Deposition in COVID-19 Post Mortem Lung Samples and Computed Tomography Analysis Findings.COVID-19 死后肺样本中胶原蛋白沉积的扩展和计算机断层扫描分析结果。
Int J Mol Sci. 2021 Jul 13;22(14):7498. doi: 10.3390/ijms22147498.
7
Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.缺氧和炎症的相互作用导致了呼吸道病毒疾病的进展和严重程度。
Mol Aspects Med. 2021 Oct;81:101000. doi: 10.1016/j.mam.2021.101000. Epub 2021 Jul 19.
8
Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms.症状出现 100 天后，重症 COVID-19 幸存者的肺功能和影像学研究出现异常。
Respir Investig. 2021 Sep;59(5):614-621. doi: 10.1016/j.resinv.2021.05.005. Epub 2021 Jun 8.
9
Post covid 19 pulmonary fibrosis. Is it real threat?新冠后肺纤维化。这是真实存在的威胁吗？
Indian J Tuberc. 2021 Jul;68(3):330-333. doi: 10.1016/j.ijtb.2020.11.003. Epub 2020 Nov 10.
10
Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.尼达尼布治疗 COVID-19 重症肺炎所致肺纤维化的疗效和安全性：一项干预性研究。
Int J Infect Dis. 2021 Jul;108:454-460. doi: 10.1016/j.ijid.2021.05.055. Epub 2021 May 25.

Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group.

作者信息

Salvi Sundeep Santosh, Ghorpade Deesha, Dhoori Sahajal, Dhar Raja, Dumra Harjit, Chhajed Prashant N, Bhattacharya Parathasarathi, Rajan Sujeet, Talwar Deepak, Christopher Devasahayam J, Mohan Murali, Udwadia Zarir

机构信息

Department of Clinical Research, Pulmocare Research and Education Foundation, Pune, Maharashtra, India.

Department of Respiratory Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Lung India. 2022 Mar-Apr;39(2):177-186. doi: 10.4103/lungindia.lungindia_659_21.

DOI:10.4103/lungindia.lungindia_659_21
PMID:35259802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9053913/
Abstract
摘要